Natureza’s Solutions Defeat Bacterial Resistance - Patent Information

Natureza Patents New Antibiotic Agents

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics.

Natureza Patents New Antibiotic Agents

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics.

#1 Compositions for internal and external insecticides, ovicides, repellents and wound healing
U.S. Patent No. 9,055,745
U.S. Patent No. 9,538,748
Canadian Patent No. 2,832,490
European Patent No. 2696677
#2 – Formulations having anti-inflammatory activity and antimicrobial activity against gram-positive bacteria
U.S. Patent No. 10,786,477
European Patent No. 3206669
#3–Small Molecule Agents, Compositions, and Formulations, for Internal Use, Displaying Inhibitory Activity Against Gram-Positive and/or Gram-Negative Organisms
U.S. Patent No. 11,351,134

Natureza’s Solutions Defeat
Bacterial Resistance

Chitosan-coated carboxylic acids show antimicrobial activity against antibiotic-resistant Gram-negative and positive pathogens.
Our novel antibiotic agents show activity against some of the deadliest multi-drug resistant pathogens and there’s NO RESISTANCE.

Antibiotic resistance in bacteria is suggested to be the greatest risk to human health, but new agents are not being brought to market as the rapid evolution of resistance to them means that drug development costs cannot be recouped. Fatty acids have been proposed as a new generation of antibiotics, but toxicity and poor absorption has meant that their use has been impractical in the past.

We have shown that chitosan can be modified to direct fatty acids towards Gram-positive or negative bacteria so that they exert antimicrobial effects and that fatty acids work as effective antibiotics in vitro and in vivo, with activity against extremely drug resistant pathogens. Bacteria exposed to them do not develop resistance to these agents, and they are not toxic to mammalian cells. Activity was seen against salmonellosis and C. difficile infection in animal models.

Our results demonstrate that fatty acids coated with chitosan are effective antibiotics, and can be used for a long period of time without resistance developing. This suggests that the usage of fatty acids coated in this manner could be sold in sufficient quantities to recoup its development costs, overcoming this barrier. These agents would form a new class of antibiotics, with the novel property of lack of bacterial resistance.

This work is protected by several US and foreign patents and patent applications.

READ THE PREPRINT